Clinical trials · Texas
Hepatocellular Carcinoma clinical trials in Texas
We’re tracking 41 recruiting hepatocellular carcinoma studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT03894917Recruiting
Study blood and imaging features in older adults with liver cancer
This study looks at what liver cancer is like in newly diagnosed people who are older and whose cancer cannot be removed by surgery. It may help doctors better understand disease behavior and how treatments may work and affect the body.
San Antonio, TexasAges 18 years+ - NCT03897543RecruitingPhase 1/Phase 2
Testing ABX196 plus nivolumab for advanced liver cancer
This trial studies whether ABX196 combined with nivolumab can slow or treat advanced hepatocellular carcinoma (liver cancer) when it can’t be fully cured with surgery or local procedures. It’s early-phase, so the goal is to find the best way to treat and whether it shows signs of benefit.
Houston, TexasAges 18 years+ - NCT04134559RecruitingPhase 2
Pembrolizumab for kids with liver cancer that came back
This trial studies pembrolizumab (an immune therapy) in children and young people with hepatocellular carcinoma (HCC) that has returned or did not respond to earlier treatment. The goal is to see whether it can shrink tumors and help control the cancer.
Houston, TexasAges birth–30 years - NCT04380545RecruitingPhase 1/Phase 2
Nivolumab plus chemo and immune drug for unresectable liver cancer
This Phase 1/2 trial tests whether nivolumab combined with fluorouracil and interferon alpha can treat fibrolamellar liver cancer that cannot be safely removed with surgery. It aims to shrink or control the cancer and to see how safe the combination is.
Houston, TexasAges 12 years+ - NCT05092373RecruitingPhase 1
Tumor treating device plus targeted or immune drugs for advanced cancers
This Phase 1 study tests whether a tumor treating fields device works better when added to standard cancer drugs. It may help people with advanced solid tumors in the chest or belly, especially when standard treatment didn’t work or can’t be tolerated.
Houston, TexasAges 18 years+ - NCT05185505RecruitingPhase 4
Atezolizumab and bevacizumab before liver transplant for liver cancer
This trial tests giving atezolizumab plus bevacizumab before liver transplant in people with hepatocellular carcinoma (HCC) that is too advanced to be listed within the “Milan criteria,” but still transplant-eligible. The goal is to control the cancer outside the transplant period and improve transplant outcomes.
Houston, TexasAges 18 years+ - NCT05440708RecruitingPhase 1/Phase 2
Study drug for advanced liver cancer that cannot be removed
This trial tests TTI-101, by itself and with other cancer medicines, for liver cancer that is advanced and cannot be removed by surgery. It aims to see whether the treatment can slow the cancer down and improve outcomes.
McAllen, TexasAges 18 years+ - NCT06600321RecruitingPhase 1
Study of ALN-BCAT for liver cancer
This trial tests a new drug called ALN-BCAT for people with advanced liver cancer (hepatocellular carcinoma) that has a specific genetic change. If you have already tried at least one treatment, this study may be an option for you.
Dallas, TexasAges 18 years+ - NCT06921785RecruitingPhase 3
Combination therapy for first-line liver cancer treatment
This trial tests a new drug combination (rilvegostomig plus bevacizumab, with or without tremelimumab) as a first treatment for people with advanced liver cancer (HCC) that cannot be removed by surgery or treated with local therapies. It aims to see if these combinations help shrink tumors or slow disease progression.
Amarillo, TexasAges 18 years+ - NCT07116486RecruitingPhase 1
Using a new PET scan to guide liver cancer treatment
This trial tests a special PET scan (18F-FSPG) to help guide therapy for people with liver cancer (HCC) who are planning to receive Y90 radioembolization. The scan may help doctors better plan your treatment.
Houston, TexasAges 18 years+ - NCT07176650RecruitingPhase 1
Testing a biosimilar ipilimumab for advanced liver cancer
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
Houston, TexasAges 18–65 - NCT05797805RecruitingPhase 1/Phase 2
Tegavivint for advanced liver cancer after prior treatments
This early-phase study tests tegavivint in people with advanced hepatocellular carcinoma (HCC), a type of liver cancer. It’s meant for cases where the cancer can’t be treated with curative surgery/local procedures or has progressed after standard systemic medicines.
Houston, TexasAges 18 years+ - NCT06109272RecruitingPhase 2/Phase 3
Livmoniplimab plus Budigalimab for liver cancer
This trial tests two investigational drugs, livmoniplimab and budigalimab, given together by IV for adults with advanced liver cancer (HCC) that cannot be removed by surgery or has spread. The study aims to see if this combination shrinks tumors and helps people live longer.
Dallas, TexasAges 18 years+ - NCT06698250RecruitingPhase 2
Study of triple therapy for untreated liver cancer
This study tests a combination of three drugs (zanzalintinib, durvalumab, and tremelimumab) for people with liver cancer that cannot be removed by surgery and who have not received prior systemic treatment. The goal is to see if this combination can shrink or slow the growth of the cancer.
San Antonio, TexasAges 18 years+ - NCT06789848RecruitingPhase 2
Testing two immunotherapy drugs for advanced liver and bile duct cancers
This trial tests two investigational drugs, ligufalimab and cadonilimab, for people with advanced liver cancer (hepatocellular carcinoma, HCC) or bile duct cancer (biliary tract cancer, BTC) that has not responded to previous treatment with an immunotherapy drug. The goal is to see if this combination can shrink tumors or slow cancer growth.
Dallas, TexasAges 18 years+ - NCT05171335Enrolling by invitationPhase 2
Lenvatinib plus TACE before transplant for large liver cancer
This trial tests whether taking lenvatinib (a targeted pill) before a liver procedure called TACE can help people with large hepatocellular carcinoma (HCC) get better results while waiting for a liver transplant. It may help shrink or control the cancer without stopping transplant plans.
Houston, TexasAges 18 years+ - NCT07175441RecruitingPhase 2
Testing a new drug combo for advanced liver cancer
This trial tests a new drug called RBS2418 added to two immunotherapy medicines (tremelimumab and durvalumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination helps patients who are starting their first treatment for this stage of liver cancer.
Dallas, TexasAges 18 years+ - NCT06427941RecruitingPhase 1
Study of BGB-B2033 drug for advanced solid tumors
This trial tests a new drug, BGB-B2033, alone or with other treatments, for people with advanced liver, stomach, lung, or germ cell cancers that have not responded to standard therapy. The goal is to see if the drug is safe and works against these tumors.
Houston, TexasAges 18 years+ - NCT05143619Recruiting
Teaching liver cancer diagnosis to radiologists worldwide
This study looks at whether a “teaching the teachers” approach improves how radiologists understand and apply liver cancer (HCC) diagnosis guidelines. It may help by standardizing how liver imaging results are interpreted across different countries and practice settings.
Houston, TexasAges Any age - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
San Antonio, TexasAges 18 years+ - NCT06526104RecruitingPhase 2
Tremelimumab and durvalumab for advanced liver cancer with Child-Pugh B
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
San Antonio, TexasAges 18 years+ - NCT06362369RecruitingPhase 1/Phase 2
Oral 7HP349 with immunotherapy for advanced solid tumors
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Houston, TexasAges 18 years+ - NCT05201404RecruitingPhase 3
Namodenoson for advanced liver cancer with moderate cirrhosis
This Phase 3 trial studies whether namodenoson can slow or control advanced hepatocellular carcinoma (liver cancer) in people whose cirrhosis is in a specific middle range. It may help if standard treatments have not worked or the cancer has spread and is not expected to be cured.
Dallas, TexasAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Houston, TexasAges 1–30
Hepatocellular Carcinoma trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting hepatocellular carcinoma studies listed above.
- The University of Texas MD Anderson Cancer Center · 9 studies
- University of Texas Southwestern Medical Center · 4 studies
- Houston Methodist Hospital · 3 studies
- Baylor College of Medicine · 2 studies
- Mays Cancer Center · 2 studies
- University of Texas Health Science Center at San Antonio · 2 studies
- Baylor Scott & White Research Institute
- Clinical Trial Site
What taking part in a hepatocellular carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Hepatocellular Carcinoma trials in other states
Common questions
- Are there hepatocellular carcinoma clinical trials in Texas?
- Yes. We're currently tracking 41 recruiting hepatocellular carcinoma studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a hepatocellular carcinoma study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New hepatocellular carcinoma studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.